Form 4: Invivyd Director Kevin F. McLaughlin Acquires Stock Options

Director Kevin F. McLaughlin acquired 100,000 stock options in Invivyd, Inc. on May 21, 2024.

Summary

• Kevin F. McLaughlin, a director of Invivyd, Inc., acquired 100,000 stock options on May 21, 2024.
• The options have an exercise price of $2.21.
• The options vest over a three-year period, starting with one-third vesting on the first anniversary of the grant date, and the remainder vesting monthly thereafter, contingent upon continuous service.
• Following the transaction, McLaughlin directly owns 100,000 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of stock options to a director suggests confidence in the company's future, but it's a routine transaction.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule suggests a long-term commitment from the director, aligning his interests with the company's success over the next three years.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options as part of their executive compensation plans to incentivize performance and align interests with shareholders.
• The vesting schedule of three years with monthly installments is a typical structure to ensure long-term commitment.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates